Testing the internal validity of the maintenance/discontinuation study design for antidepressant medications in depression using simulations

Enrichment by randomizing only remitters in major depressive disorder simulations increases simulated antidepressant benefit 1.7-fold (1.75 to 2.91 HRSD points) and matches observed relapse patterns.

• Why it matters: Maintenance/discontinuation trials show larger long-term benefits than acute-phase effects suggest, raising concerns that post-improvement selection may bias internal validity.
• What they did: The study simulated maintenance/discontinuation trials using averaged design parameters from nine trials, symptom fluctuations from STAR*D, and drug effects from placebo-controlled acute-phase trials, then compared simulated relapse rates and relative risks to withheld aggregated outcomes.
• The result: Under modeled assumptions, simulated relapse rates and relative risks agreed with observed trial outcomes by the model-fit criterion, supporting internal validity for estimating continued treatment benefits among medication remitters.

AI summary of the abstract · may contain errors · not medical advice · read the paper.